Which molecular-targeted agents are FDA-approved for treatment of renal cell carcinoma (RCC)?

Updated: Feb 19, 2021
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print

The introduction of molecular-targeted therapy has essentially altered the management of advanced renal cell carcinoma (RCC). Molecular-targeted agents approved by the US Food and Drug Administration (FDA) for treatment of metastatic kidney cancer include the following:

  • Sunitinib
  • Bevacizumab in combination with interferon
  • Pazopanib
  • Temsirolimus
  • Everolimus
  • Lenvatinib in combination with everolimus
  • Nivolumab (plus ipilimumab or cabozantinib)
  • Avelumab in combination with axitinib
  • Cabozantinib
  • Sorafenib
  • Axitinib
  • Avelumab
  • Pembrolizumab

These targeted agents have gained wide use as first-line, second-line, and subsequent-line therapy. The optimal sequence of their use as targeted agents is not yet defined, however.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!